SCHEMBL14747878

SCHEMBL14747878

Cc1cc(C2C=CC(O)=CC2)ccc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 11/20 0.39
ESR2 Q92731 9/20 0.39
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PDE10A Q9Y233 1/20 0.35
AR P10275 3/20 0.33
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
HSP90AA1 P07900 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPT P10636 1/20 0.31
G6PD P11413 1/20 0.31
CYP2C9 P11712 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17754284 0.75 ESR2 (0.35) ESR1ESR2MEN1NPC1RAB9A
SCHEMBL27704603 0.75 KDM4E (0.44) ESR1ESR2KDM4ECYP1A2CYP2D6
SCHEMBL2830279 0.74 HSD17B1 (0.38) ESR1ESR2TP53TDP1ALDH1A1
SCHEMBL22238273 0.72 ESR1 (0.32) ESR1ESR2TP53TDP1
SCHEMBL2718567 0.70 ESR2 (0.41) ESR1ESR2TP53TDP1PDE10A
SCHEMBL6758132 0.70 TP53 (0.39) ESR1ESR2TP53TDP1PDE10A
SCHEMBL14048659 0.68 TP53 (0.45) ESR1ESR2TP53TDP1PDE10A
SCHEMBL27991830 0.68 TP53 (0.37) ESR1ESR2TP53TDP1PDE10A
SCHEMBL930211 0.67 QDPR (0.52) ESR1ESR2TP53TDP1PDE10A
SCHEMBL31574437 0.67 TP53 (0.48) ESR1ESR2TP53TDP1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275413-B1 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2013-03-06 EP disclosed